Regarding composite outcome in the main analysis, after excluding patients with a history of heart failure, stroke, and myocardial infarction, 72,556 and 39,214 new users of DPP-4 and SGLT2 inhibitors, including 18,325 and 9,478 who initiated drug use at hospitals, respectively, were analyzed. This evidence concerns the gene SLC5A2 and stroke disorder.